Syndax Pharmaceuticals
SNDX
166 hedge funds and large institutions have $1.48B invested in Syndax Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 83 increasing their positions, 42 reducing their positions, and 19 closing their positions.
98% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 42
21% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 19
2% more funds holding
Funds holding: 163 → 166 (+3)
4% less capital invested
Capital invested by funds: $1.54B → $1.48B (-$61.9M)
3.97% less ownership
Funds ownership: 106.65% → 102.67% (-4%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
52% less call options, than puts
Call options by funds: $2.23M | Put options by funds: $4.69M
Top Buyers
| 1 |
O
OrbiMed
New York
|
+$17M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$14.8M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$12.7M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$10.6M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$9.89M |
Top Sellers
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$45.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$28M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$20.7M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$19.4M |
| 5 |
Barclays
London,
United Kingdom
|
-$16.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Victory Capital Management
San Antonio,
Texas
| – | -$339K | -16,033 | Closed |
|
|
FRM
177
Fox Run Management
Greenwich,
Connecticut
| – | -$279K | -13,214 | Closed |
|
|
PCM
178
Prelude Capital Management
New York
| – | -$231K | -10,943 | Closed |
|
|
CSS
179
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$167K | -7,920 | Closed |
|
|
SOW
180
State of Wyoming
Cheyenne,
Wyoming
| – | -$68.5K | -3,242 | Closed |
|
|
DFCM
181
Dark Forest Capital Management
San Juan,
Puerto Rico
| – | -$10.6K | -502 | Closed |
|
|
TWA
182
TCI Wealth Advisors
Tucson,
Arizona
| – | -$5.93K | -281 | Closed |
|
183
Fisher Asset Management
Camas,
Washington
| – | -$3.1K | -147 | Closed |
|
|
EWA
184
EverSource Wealth Advisors
Birmingham,
Alabama
| – | -$1.35K | -64 | Closed |
|
|
C
185
Covestor
London,
United Kingdom
| – | -$271 | -13 | -68% |
|
SNDX Hedge Fund Activity: Q2 2023 in Review
166 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q2 2023, worth a combined $1.48B — down 4% from $1.54B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new SNDX positions and 19 closed out — a net gain of 4 holders — while 83 added to existing stakes and 42 trimmed.
The largest buyer was OrbiMed, adding an estimated $17M. The largest seller was BVF Inc, exiting entirely with an estimated $45.3M sold.
- 166 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q2 2023, up from 163 in Q1 2023.
- Funds reported $1.48B of Syndax Pharmaceuticals stock for Q2 2023, down 4% quarter-over-quarter.
- 23 funds opened new Syndax Pharmaceuticals positions in Q2 2023 and 19 closed out, a net change of +4 holders.
- The largest Syndax Pharmaceuticals buyer in Q2 2023 was OrbiMed, an estimated $17M added.
- The largest Syndax Pharmaceuticals seller in Q2 2023 was BVF Inc, an estimated $45.3M sold.
Based on aggregated 13F filings for Q2 2023.